Pangrati,
"One institutional investor has subscribed for the Placing Shares"
Which translates as: a market-maker has being selling (short) to punters for a while and has now subscribed for shares to cover their short.
JakNife |
One institutional investor has subscribed for the Placing Shares |
Vlad has been deceiving shareholder for many years, most of that money raised for the last 5 years has been used to pay high salaries for the highly incompetent management.
Vlad is a deceiver, just look at the share price, what value has he delivered for the shareholders in the last 5 years. |
Mad vlad strikes again huh. When will the gerbils learn? |
 Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares") at a price of 340p per share (the "Placing"). One institutional investor has subscribed for the Placing Shares and has also been granted 50,000 warrants exercisable at a price of 500p each for a period of 12 months from 1 March 2025.
The Placing uses the Company's current headroom to issue ordinary shares for cash. The net proceeds of the Placing will be dedicated to the clinical trial of the Company's lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. The first patient for the trial is recruited and being tested for inclusion/exclusion criteria to satisfy the clinical protocol. The funds raised will also assist the Company into the next stage of the trials.
An application is being made to the Main Market of the London Stock Exchange, and admission of the Placing Shares to trading is expected on or around 15 January 2025 ("Admission"). The Placing Shares will rank pari passu with the Company's existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 3,604,539 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules. |
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has raised £340,000 through the issue of 100,000 new ordinary shares ("Placing Shares") at a price of 340p per share (the "Placing"). One institutional investor has subscribed for the Placing Shares and has also been granted 50,000 warrants exercisable at a price of 500p each for a period of 12 months from 1 March 2025.
The Placing uses the Company's current headroom to issue ordinary shares for cash. The net proceeds of the Placing will be dedicated to the clinical trial of the Company's lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. The first patient for the trial is recruited and being tested for inclusion/exclusion criteria to satisfy the clinical protocol. The funds raised will also assist the Company into the next stage of the trials.
An application is being made to the Main Market of the London Stock Exchange, and admission of the Placing Shares to trading is expected on or around 15 January 2025 ("Admission"). The Placing Shares will rank pari passu with the Company's existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 3,604,539 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules. |
I bought a few more today (A couple of hours ago) and it's still not showing |
Pathetic attempt to save the share price today. Huge rinse coming. |
Was looking at investing here but completely put off by the youtube interview. Extremely unconvincing presentation particularly by the couldnt care or less attitude by the guy in the sweater. The science may be good but I cant see those two attracting any seriouse investment. Have either a proven track record in business?
Its a real shame as I am very attracted by the project. |
Jackknife is coining it in again.Follow him and you will always be rich. |
Low liquidity main course of drop ! Future Funding is a concern! Good partnership rns will see it fly may be |
It's being played |
Not long at the rate it's going . Talk about one to short |
How long before this gets back down to 1p? |
Im in at 250p.... I have the patience, but,...... It'll not be a long wait .. :0))) |
This is done for No one will buy |
Now equivalent to 0.9p. |
JackNife's pockets are endless and his shorts are hammering the price and the company will be forced to do a 0.5p placing.Without JackNife this would of never gone to 1p and the placing would of been at a premium and my bet would of never been stopped out and now I be showing a huge profit. JackNife is what keeps the spread bet company's happy. |
You can see how JackNife shorts always wins since he keeps on increasing huge shorting trades to force the price down. |
It makes sense how I get such a buzz out of trolling JackNife in every way I can. One thing people hate to see is someone having such success and I feel the same and especially when it is out of the misery of shorting peoples dreams. |
Looks like 0.5p at Hemo in the short term. I wonder what JackNife profits margin will look like then. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
